Alimentary pharmacology & therapeutics · 2025
Research Communication: Comparative Effectiveness of Ustekinumab and Vedolizumab in the Management of Chronic Pouchitis-A Population-Based Study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alsakarneh Saqr, Tome June, Farraye Francis A, Pardi Darrell S
Аннотация
INTRODUCTION: Chronic pouchitis is a major therapeutic challenge in patients with ulcerative colitis following ileal pouch-anal anastomosis.
METHODS: We conducted a real-world, propensity-matched cohort study of 856 patients from a healthcare database to compare ustekinumab and vedolizumab.
RESULTS: Ustekinumab was associated with significantly lower relapse rates (aHR = 0.69; p < 0.001), longer time to relapse, reduced hospitalisation and decreased need for steroids or antibiotics. No differences were observed in surgery rates or therapy switching.
CONCLUSION: Our findings suggest that ustekinumab may offer advantages over vedolizumab in the management of chronic pouchitis.
METHODS: We conducted a real-world, propensity-matched cohort study of 856 patients from a healthcare database to compare ustekinumab and vedolizumab.
RESULTS: Ustekinumab was associated with significantly lower relapse rates (aHR = 0.69; p < 0.001), longer time to relapse, reduced hospitalisation and decreased need for steroids or antibiotics. No differences were observed in surgery rates or therapy switching.
CONCLUSION: Our findings suggest that ustekinumab may offer advantages over vedolizumab in the management of chronic pouchitis.